Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerRevolutionizing Alzheimer's disease and clinical trials through biomarkersUnfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion DiseasesThe genetic landscape of Alzheimer disease: clinical implications and perspectivesAutosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical ADLymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?Monitoring of 30 marker candidates in early Parkinson disease as progression markers.Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Studyd-serine levels in Alzheimer's disease: implications for novel biomarker developmentThe sleep-wake cycle and Alzheimer's disease: what do we know?Tau PET imaging: present and future directions.Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional studyAssociations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional studyLong-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's diseasePlasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers.Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort studyIncreased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models.Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis.Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of AgeThe Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target PopulationsAbnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findingsAge-dependent inverse correlations in CSF and plasma amyloid-β(1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD miceAn Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjectsLongitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year studyChanges in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's diseaseCerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Alzheimer's disease genetics: from the bench to the clinic.Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
P2860
Q26738703-B0717600-B4DA-4D43-9D77-056208C2EBA2Q26744882-0D534843-ACC4-4702-A38B-C8C19B7E48FFQ26773443-120928EB-F41A-4295-99E1-89BF32E8B15CQ26796582-71985B9D-4153-48F4-BD48-24DFFD2A0F31Q26801666-31DE0C9C-AEF8-46C2-AE6F-C68AFE79F49FQ30275974-D07790E8-F6AA-44B9-951F-ECF1A7BB998CQ30783504-9C6877C5-0A6A-4F60-B3FB-3D4B56C81000Q30981669-F874DA7D-DDEB-4450-8983-A43B6CAC0631Q33769278-E017EABD-E00F-4AC7-8E9D-8513F65DD069Q33894452-356FC737-CAA1-412E-A7C0-ACD305D2180CQ34475073-E568497B-141E-45F3-877D-66B414F554F3Q34637928-5962D130-7D6F-494C-84E9-94A27F2E00D9Q34680852-3248AD04-C47E-445D-AB1F-D2C72B5C3808Q35073049-EDE9D5FB-7CE9-4875-BADB-16854EAEA229Q35164302-4BE19E6B-5224-4A42-8B82-2BAB27985407Q35540628-B518C413-ADB5-4F20-BA81-991CFD567692Q35795155-E6EDB57B-917E-4D13-A55E-DAB564168365Q35800785-D81DAA03-4A3C-4539-9979-BBB38C1CEBAEQ35900301-E86794FC-99E9-4898-B97A-01A75790D9EEQ35904243-03ADF5A0-9DC1-45EE-8713-FF508D7B6C43Q36001286-013B199E-DFE2-4255-B6F7-341CD98F346CQ36017239-0E326293-65DD-41DE-99F5-564AC8534195Q36062391-378C6B5A-B186-4CDB-AD6F-9E157774E0B2Q36071742-E613B172-31D8-46F4-A7E2-A1116AD1DE65Q36105614-DB94D186-94A6-428A-934B-388915B2B179Q36165011-9A86B4E8-230B-46A0-8F76-6B38E71C7E0CQ36209842-3E960FE7-7E0C-409D-8DBC-D20AD011AE34Q36276506-820D1C0E-1649-4F7B-9170-47E929AA504AQ36305487-2B58A8DC-316D-46B1-85EB-2386C7FDDC77Q36528218-208EB632-C7B3-46EE-8392-E73DFD090921Q36739111-CF85B96E-F25B-4F27-B45D-58B605AFF92AQ36806654-E96841FD-9ABE-4B5E-AA7C-980F375D3535Q36813260-D7E5C78C-F3A5-4C78-A024-17D54ED1F7D7Q36933698-BAA12C18-36E8-496B-BEB6-F4D29A4204F8Q37067687-FD406746-A5CC-4F09-9C87-A815B657B78EQ37272348-1D92A20A-5E5F-4506-8516-9DF30CEF8F60Q37743591-CD9AD5D0-EF4F-4F0C-9939-31D2CF41E329Q38224958-A939674D-8423-4CF8-9871-404118822700Q38225911-CC83B7D7-F554-4C6D-BC2A-4D0BD455FFF8Q38235780-F075B4AC-21E0-44BD-84C0-03DC20352DEE
P2860
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
@ast
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
@en
type
label
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
@ast
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
@en
prefLabel
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
@ast
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
@en
P2093
P2860
P50
P1476
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
@en
P2093
Bernardino Ghetti
Chengjie Xiong
Daniel Marcus
Jack H Ladenson
John M Ringman
Mateusz S Jasielec
Nigel J Cairns
Reisa A Sperling
Stephen Salloway
Tammie L S Benzinger
P2860
P304
P356
10.1126/SCITRANSLMED.3007901
P407
P50
P577
2014-03-01T00:00:00Z